Literature DB >> 33895916

Ozonated oil effect for prevention of medication-related osteonecrosis of the jaw (MRONJ) in rats undergoing zoledronic acid therapy.

C G J Monteiro1, E M Vieira1, C Emerick1, R S Azevedo1, V A B Pascoal1, N Homsi1, R X Lins2.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the preventive effect of ozonated oil on the development of MRONJ-like lesions at tooth extraction sites in rats submitted to zoledronic acid treatment.
MATERIALS AND METHODS: Twelve rats were divided into two groups. Each rat received an injection of zoledronic acid solution once a week for 5 weeks before having its upper first molar extracted. In group 1, the clotted socket was maintained, while in the group 2, the socket was treated with ozonated oil for 10 min/day during 3 days. After euthanasia, block resection was performed for histological analysis. Necrotic bone was defined as the area of the bone with empty osteocyte lacunae and vital bone as the area with osteocyte-occupied lacunae.
RESULTS: There was no statistically significant difference between the groups in the average area of vital bone (p = 0.2248) and the average area of necrotic bone (p = 0.1208). However, the average area of vital bone in group 1 was smaller (24.1 ± 2.9 cells/cm2) than in group 2 (26.8 ± 4.2 cells/cm2), and the average area of necrotic bone in group 1 was higher (7.0 ± 2.5 cells/cm2) than in group 2 (4.0 ± 1.1 cells/cm2), indicating that ozonated oil may reduce the development of osteonecrosis.
CONCLUSIONS: Our findings suggest that ozonated oil might prevent MRONJ-like lesions at tooth extraction sites in rats submitted to a disease induction protocol. Further research should be conducted to confirm this hypothesis. CLINICAL RELEVANCE: MRONJ has been reported as a complication of surgical dental procedures, and there are currently no predictable preventive therapies.

Entities:  

Keywords:  Animal experimentation; Bisphosphonate; MRONJ; Osteonecrosis; Ozone

Year:  2021        PMID: 33895916     DOI: 10.1007/s00784-021-03951-3

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  34 in total

1.  Bisphosphonate-induced osteopetrosis.

Authors:  Michael P Whyte; Deborah Wenkert; Karen L Clements; William H McAlister; Steven Mumm
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

2.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

Review 3.  Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.

Authors:  Jose V Bagan; Yolanda Jimenez; Judith Murillo; Sergio Hernandez; Rafael Poveda; José M Sanchis; José M Diaz; Crispian Scully
Journal:  Oral Oncol       Date:  2005-11-04       Impact factor: 5.337

Review 4.  Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.

Authors:  Giuseppe Ficarra; Francesco Beninati
Journal:  Head Neck Pathol       Date:  2007-12-05

5.  Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.

Authors:  Sebastian Hoefert; Harald Eufinger
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-08-09

Review 6.  Biophosphonate-related osteonecrosis of the jaws.

Authors:  Salvatore L Ruggiero; Sook-Bin Woo
Journal:  Dent Clin North Am       Date:  2008-01

7.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

8.  A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders.

Authors:  H Murakami; N Takahashi; T Sasaki; N Udagawa; S Tanaka; I Nakamura; D Zhang; A Barbier; T Suda
Journal:  Bone       Date:  1995-08       Impact factor: 4.398

9.  Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.

Authors:  D E Hughes; K R Wright; H L Uy; A Sasaki; T Yoneda; G D Roodman; G R Mundy; B F Boyce
Journal:  J Bone Miner Res       Date:  1995-10       Impact factor: 6.741

10.  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

Authors:  D E Hughes; B R MacDonald; R G Russell; M Gowen
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

View more
  2 in total

Review 1.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

Review 2.  Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  Ran Yan; Ruixue Jiang; Longwei Hu; Yuwei Deng; Jin Wen; Xinquan Jiang
Journal:  Int J Oral Sci       Date:  2022-08-10       Impact factor: 24.897

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.